Small blue round cell tumors (SBRCTs) are a heterogenous group of tumors that are difficult to diagnose because of overlapping morphologic, immunohistochemical, and clinical features. About two-thirds of EWSR1-negative SBRCTs are associated with CIC-DUX4-related fusions, whereas another small subset shows BCOR-CCNB3 X-chromosomal paracentric inversion. Applying paired-end RNA sequencing to an SBRCT index case of a 44-year-old man, we identified a novel BCOR-MAML3 chimeric fusion, which was validated by reverse transcription polymerase chain reaction and fluorescence in situ hybridization techniques. We then screened a total of 75 SBRCTs lacking EWSR1, FUS, SYT, CIC, and BCOR-CCNB3 abnormalities for BCOR break-apart probes by fluorescence in situ hybridization to detect potential recurrent BCOR gene rearrangements outside the typical X-chromosomal inversion. Indeed, 8/75 (11%) SBRCTs showed distinct BCOR gene rearrangements, with 2 cases each showing either a BCOR-MAML3 or the alternative ZC3H7B-BCOR fusion, whereas no fusion partner was detected in the remaining 4 cases. Gene expression of the BCOR-MAML3-positive index case showed a distinct transcriptional profile with upregulation of HOX-gene signature, compared with classic Ewing's sarcoma or CIC-DUX4-positive SBRCTs. The clinicopathologic features of the SBRCTs with alternative BCOR rearrangements were also compared with a group of BCOR-CCNB3 inversion-positive cases, combining 11 from our files with a meta-analysis of 42 published cases. The BCOR-CCNB3-positive tumors occurred preferentially in children and in bone, in contrast to alternative BCOR-rearranged SBRCTs, which presented in young adults, with a variable anatomic distribution. Furthermore, BCOR-rearranged tumors often displayed spindle cell areas, either well defined in intersecting fascicles or blending with the round cell component, which appears distinct from most other fusionpositive SBRCTs and shares histologic overlap with poorly differentiated synovial sarcoma.
T he differential diagnosis of primitive small blue round cell tumors (SBRCTs) poses a challenge to both pathologists and clinicians because of overlapping morphologic, immunohistochemical, and clinical features. Ewing's sarcoma (ES) is the prototypical SBRCT molecularly characterized by canonical fusions between EWSR1 and a gene of the ETS family of transcription factors. The molecular landscape of SBRCTs with Ewinglike morphology has been further expanded by the discovery of fusions of EWSR1 with alternative non-ETS partners, 1 with EWSR1-NFATc2 fusion being one of the more common events in this class, being associated with amplification of the fusion transcript. 2 Another subset of SBRCTs sometimes referred to as "ES-like" or "atypical ES" comprise sarcomas with CIC-DUX4 fusion resulting from either a t(4;19)(q35;q13) or a t(10;19)(q26;q13). [3] [4] [5] [6] The CIC-DUX4 fusion appears functionally unrelated to EWSR1-ETS, and the reported distinct gene signature and immunoprofile of CIC-DUX4 sarcomas suggest a pathogenesis distinct from ES. 3, 7 The morphologic appearance of CIC-DUX4 sarcomas is less monotonous compared with classic ES, with slight nuclear pleomorphism, vesicular chromatin with focally prominent nucleoli, more abundant cytoplasm, areas of spindling, and myxoid matrix. 6, 8 Clinically, CIC-DUX4positive tumors are highly aggressive, arising almost exclusively in deep soft tissue of young adults.
More recently, Pierron et al 9 identified a fusion between BCOR (encoding the BCL6 transcriptional corepressor) and CCNB3 (encoding the testis-specific cyclin B3) in SBRCTs with ES-like morphology, resulting from an X-chromosomal paracentric inversion, which links the BCOR coding sequence to the CCNB3 exon 5. Although BCOR-CCNB3-positive SBRCTs share certain similarities with ES, such as clinical presentation often in bone and some morphologic and immunohistochemical overlap, [10] [11] [12] they show a distinct gene expression profile and copy number changes compared with classic ES. 9 Whether these newly identified genetic entities represent stand-alone categories of tumors or should be subsumed under the ES family of tumors is still a matter of debate. At present, the number of reported cases carrying a CIC-DUX4 or BCOR-CCNB3 fusion is still limited. Nevertheless, distinction of these SBRCT subsets appears important from a clinical and therapeutic point of view, to allow prospective therapeutic management with selection of proper chemotherapeutic regimens or target-specific therapy. 13 In this study, we attempted to further characterize the molecular spectrum of ES-like tumors using nextgeneration RNA sequencing for novel gene fusion discovery in an index case. Subsequently, validated abnormalities were then screened in a large cohort of primitive unclassified SBRCTs negative for EWSR1/ FUS/SYT/CIC-related fusions.
MATERIALS AND METHODS
The personal consultation files of the senior authors (C.R.A., C.D.M.F.) and the Pathology files of Memorial Sloan Kettering Cancer Center, New York, NY (C.R.A.), and the Technische Universita¨t Mü nchen, Germany (K.S.), were searched for cases with a diagnosis of SBRCT or ESs, with tissue available for further immunohistochemical and molecular analysis. A total of 86 SBRCTs lacking EWSR1, FUS, SYT, and CIC gene rearrangements were identified. From these, 11 cases (13%) were found to be positive for the BCOR-CCNB3 paracentric inversion. The remaining 75 cases represented our study group. In one of these cases (SBRCT1) there was available frozen tissue for RNA sequencing and gene fusion detection. Morphology and previously performed immunohistochemical staining were reviewed in all cases. All cases were handled in accordance with the ethical rules of the respective institutions.
RNA Sequencing
Total RNA was prepared from the index case for RNA sequencing according to the Illumina mRNA sample preparation protocol (Illumina). Briefly, mRNA was isolated with oligo(dT) magnetic beads from total RNA (10 mg) extracted from fresh-frozen tissue. Fragmentation of mRNA was performed at 941C for 2.5 minutes in fragmentation buffer (Illumina). Before the adapter ligation step, an additional size-selection step (capturing 350 to 400 bp) was introduced to reduce inclusion of artifactual chimeric transcripts due to random priming of transcript fragments into the sequencing library. 14 Enrichment of the adapter-ligated library was achieved by polymerase chain reaction (PCR) for 15 cycles. After purification, the library was sized and quantified using the DNA1000 Kit (Agilent) on an Agilent 2100 Bioanalyzer according to the manufacturer's instructions. Paired-end RNA sequencing at read lengths of 50 to 51 bp was performed with the HiSeq 2500 (Illumina). A total of about 97 million paired-end reads were generated, corresponding to about 9.7 billion bases.
Analysis of RNA Sequencing Results With FusionSeq
Reads were independently aligned with STAR alignment software against the human genome reference sequence (hg19) and a splice junction library, simultaneously. 15 After conversion of mapped reads into Mapped Read Format, 16 analysis was performed using Fu-sionSeq. 17 FusionSeq is a computational method that has been successfully applied to paired-end RNA-seq data for the identification of chimeric fusion transcripts. 9, [18] [19] [20] Briefly, in a first step, paired-end reads mapping to different genes were used to identify potential chimeric candidates. A cascade of filters, each taking into account different sources of noise in RNA-sequencing experiments, were then applied to remove spurious fusion transcripts. After generation of a confident list of fusion candidates, they were ranked to prioritize experimental validation. 17 Table 1 , Supplemental Digital Content 1, http://links.lww.com/PAS/A329). BAC clones were chosen according to the UCSC genome browser (http://genome.ucsc.edu) and were obtained from BAC-PAC sources of Children's Hospital of Oakland Research Institute (Oakland, CA) (http://bacpac.chori.org). DNA was isolated, labeled with different fluorochromes in a nick translation reaction, denatured, and hybridized to pretreated slides as described previously. Two hundred tumor nuclei were evaluated using a Zeiss fluorescence microscope (Zeiss Axioplan, Oberkochen, Germany), controlled by Isis 5 software (Metasystems). A cutoff of >20% nuclei showing a break-apart signal was considered to be positive for rearrangement. Nuclei with an incomplete set of signals were omitted from the score.
Interphase Fluorescence In Situ Hybridization

Reverse Transcription Polymerase Chain Reaction
An aliquot of the RNA extracted above from frozen tissue (Trizol Reagent; Invitrogen, Grand Island, NY) was used to confirm the fusion transcript identified by FusionSeq. RNA quality was determined by Eukaryote Total RNA Nano Assay, and cDNA quality was tested for PGK housekeeping gene (247 bp amplified product). Total RNA of 1 mg was used for cDNA synthesis by SuperScript III First-Strand Synthesis Kit (Invitrogen, Carlsbad, CA). Reverse transcription polymerase chain reaction (RT-PCR) was performed using the Advantage-2 PCR kit (Clontech, Mountain View, CA) for 32 cycles at an annealing temperature of 641C. The primers used were as follows: BCOR exon 15 fwd: 5 0 -GTCCTCCCGCATA TTTCGC-3 0 ; MAML3 exon 2 rev: 5 0 -CCTGAAACCT TCTTTGCCCTTG-3 0 . Amplified products were purified and sequenced by the Sanger method.
Gene Expression Profiling
Total RNA from fresh-frozen tissue extracted from SBRCT1 harboring a BCOR-MAML3 fusion was labeled and hybridized onto an Affymetrix Human Gene 1.0 ST array (32,000 transcripts). The transcriptional profile was then compared with the expression of a large spectrum of normal tissues (n = 16), studied on the same platform. The transcriptional signature was further compared with a previously published comprehensive gene expression metaanalysis of ES and CIC-DUX4-fusion-positive SBRCTs. 7 For data analysis, Robust Multi-array Average normalization was performed, including background correlation, quantile normalization, and the median polish summary method. 21 Subsequent analysis was carried out with signal intensities that were log2-transformed to remove biases based on signal expression values. 22 Statistical t test and false discovery rate were performed to identify the differentially expressed gene list, and subsequent hierarchical clustering was accomplished by heatmap function in R and bioconductor. 23 Annotation files for Affymetrix Human Gene arrays were obtained from the Affymetrix website (http://www.affymetrix.com/support/technical/annotationfilesmain.affx) and analyzed using PERL script to match the probe IDs. Subsequently, gene set enrichment analysis (GSEA) was performed for investigating statistical associations between variable gene sets and phenotype of interest. 24 The algorithm in GSEA calculates the enrichment score, with corresponding significance level based on permutation tests (empirical P-values and false discovery rates controlling global false positives). Each sample group was permutated 1000 times to yield statistical significance.
RESULTS
The index case was that of a 44-year-old male patient who presented with a large intra-abdominal mass, clinically refractory to chemotherapy and radiotherapy (Figs. 1A-C). Morphologically, the tumor was classified under the ES family of tumors, showing sheets of primitive round to ovoid cells set in a slightly collagenized background ( Fig. 1D ). Tumor cells displayed finely stippled chromatin, scant eosinophilic cytoplasm, mild pleomorphism, and a high mitotic rate ( Fig. 1E ). After chemotherapy, there was no significant tumor response in the form of stromal fibrosis or changes in cytomorphology ( Fig. 1F ). Immunohistochemically, strong CD99 membranous positivity was noted (Fig. 1G ). The tumor lacked the pathognomonic gene fusions characteristic for ESnamely, EWSR1 and FUS-and was also negative for CIC rearrangement and BCOR-CCNB3 inversion by FISH.
FusionSeq data analysis identified a BCOR-MAML3 fusion as the top candidate. Alignment of the reads suggested a fusion of BCOR exon 15 to MAML3 exon 2 ( Figs. 2A, B ), a transcript that was subsequently confirmed by RT-PCR (Fig. 2C ). The RNAseq further showed significant upregulation of both BCOR and MAML3 mRNAs, compared with other translocationpositive sarcomas (Fig. 2D ). As predicted from the structure of the chimeric BCOR-MAML3 fusion, only MAML3 exons 2 to 6 were significantly upregulated in the index case but not in the other sarcomas ( Fig. 2D ).
Two Recurrent BCOR-related Fusions are Identified in SBRCT, Involving MAML3 and ZC3C7B Partner Genes
To further confirm the BCOR-MAML3 fusion at the genomic level, FISH experiments were conducted using custom BAC probes flanking the centromeric and telomeric regions of BCOR and MAML3, respectively. A break-apart split signal was seen in both BCOR ( Fig. 3A) and MAML3 ( Fig. 3B ) genes. A 3-color fusion FISH assay was also used, confirming the colocalization of BCOR (red) with MAML3 (yellow, centromeric) and the split of the green (telomeric) and yellow (centromeric) MAML3 (Fig. 3C ).
Among the 75 SBRCTs negative for all known fusions, such as EWSR1, FUS, SYT, CIC, and the BCOR-CCNB3 inversion, a total of 8 (11%) tumors showed other BCOR gene rearrangements on using the BCOR breakapart FISH assay ( Table 1 ). The subsequent FISH screening for potential partners identified BCOR-MAML3 fusion in an additional case, whereas the remaining 6 cases showed no abnormalities in MAML3. Upon review of the literature for additional BCOR gene partners we identified ZC3H7B as a potential candidate, having been described in BCOR-ZC3H7B fusions in other sarcomas. 20, 25 Thus, we screened the remaining 6 BCOR-rearranged cases for ZC3H7B gene break-apart by FISH and found 2 positive cases. One of the cases showed an unbalanced ZC3H7B break-apart with deletion of the telomeric signal (SBRCT4, Supplementary Fig. 1 , Supplemental Digital Content 2, http://links.lww.com/PAS/A330), whereas the other showed a balanced ZC3H7B rearrangement (SBRCT3, data not shown). In the remaining 4 BCORrearranged cases no gene partner was identified.
Clinicopathologic Characteristics of BCORrearranged SBRCTs (Excluding BCOR-CCNB3positive Cases)
All patients except 1 were male, with a mean and median age at diagnosis of 35 and 39 years, respectively (range, 5 to 70 y). Three cases arose in somatic soft tissue (upper extremity, groin/thigh, lower leg) ( Supplementary  Fig. 1 , Supplemental Digital Content 2, http://links. lww.com/PAS/A330), 2 in the intra-abdominal/pelvic region, 2 cases in bone (ilium and skull base), and 1 tumor in the lung. Tumor size tended to be large (mean, 13 cm). On the basis of the limited clinical data available (Table 1) , most patients followed an aggressive clinical course, despite intensive radiotherapy and/or chemotherapy.
On microscopic examination, the BCOR-MAML3positive and BCOR-ZC3H7B-positive tumors were characterized by a solid growth of undifferentiated cells (Fig. 1D) , often exhibiting infiltrative borders into adjacent anatomic structures, such as skeletal muscle or adipose tissue. The tumors were composed of a proliferation of primitive and relatively monomorphic smallsized to medium-sized cells, with scant amphophilic or lightly eosinophilic cytoplasm, round to oval nuclei, with minor variation in size and shape (Fig. 1D ). All except 2 cases showed a spindle cell component either arranged in intersecting fascicles, reminiscent of herring-bone growth pattern (Figs. 4A-C), or in a less defined, storiform or patternless growth. The spindle cell areas varied significantly from case to case either from being focal to comprising >30% of the tissue examined. In the remaining 2 cases lacking a distinct spindle cell component, the round cell component blended with cells that showed more oval to short spindled morphology. Areas of myxoid or edematous stromal change were also noted ( Fig. 4E ). Geographic tumor necrosis was common and prominent in the majority of cases, with frequent apoptosis and individual tumor cell necrosis (Fig. 4F ). No rosette formation was observed.
Immunohistochemical Findings
The results of the immunohistochemical findings are summarized in Table 2 . CD99 staining was seen in 6/7 BCOR-rearranged cases tested but was quite variable, being strong and diffuse only in the index case ( Fig. 1G , Table 2 ) while being weak and patchy in the remaining lesions. One case was completely negative for CD99. Positivity for cytokeratins (1/8) and desmin (1/8) was rarely seen. All cases were negative for S100 protein and WT1, and 1 case tested was negative for CCNB3 (SBRCT1, data not shown).
A Distinct Gene Expression Signature of BCOR-MAML3-positive Sarcoma
We first determined the BCOR-MAML3-associated gene expression signature of the SBRCT1 index case by using the Affymetrix Human Gene 1.0 ST arrays in comparison with a wide spectrum of 16 normal tissues. 7 Thus, a 645-gene list of differentially expressed genes was identified (fold change >1.4). Interestingly, among the highest ranked upregulated genes there were a significant number of genes from the homeobox (HOX) family ( Supplementary Fig. 2 , Supplemental Digital Content 3, http://links.lww.com/PAS/A331). Also part of the BCOR-MAML3 signature was the upregulation of both BCOR and MAML3 mRNA expression, which confirmed the RNA sequencing results of SBRCT1 (Fig. 2D ).
Using the VENN diagram tool, the above BCOR-MAML3 gene signature was compared with the previously defined CIC-DUX and EWSR1-FLi1 transcriptional signatures, 7 which revealed a limited overlap between these 3 SBRCT genetic subsets (Supplementary Fig. 3 , Supplemental Digital Content 4, http:// links.lww.com/PAS/A332). The poor correlation between the BCOR-MAML3 gene signature and the clustering of both CIC-DUX and EWSR1-FLI1 SBRCT subsets was further confirmed by GSEA analysis ( Supplementary  Fig. 3 , Supplemental Digital Content 4, http://links. lww.com/PAS/A332).
BCOR-CCNB3-positive SBRCTs Have Characteristic Clinicopathologic Features
Among 86 SBRCTs lacking EWSR1, FUS, SYT, and CIC gene rearrangements initially tested for BCOR abnormalities using a FISH assay designed to detect the BCOR-CCNB3 paracentric inversion, 11 cases (13%) were positive for the BCOR-CCNB3 fusion. All except 1 were male, with a median age of 15 years (range, 2 to 44 y; mean, 15 y). In fact, all except 2 cases occurred in children and originated in the bone. These findings are in keeping with the clinicopathologic features of the 42 cases obtained from the meta-analysis of published cases, [9] [10] [11] [12] showing a similar median age of 13 years at diagnosis, preferentially occurring in the male population and at bone locations (Table 3 ). These clinical findings are somewhat different from the other BCOR-rearranged SBRCTs, which had an older age at diagnosis (median of 39 y) and a more variable anatomic distribution between bone, soft tissue, and the intra-abdominal/visceral region.
DISCUSSION
Undifferentiated round cell sarcomas are a heterogenous group of tumors that often affect children and young adults. Correct classification is critical for patient management, as well-defined subtypes of ES-like tumors require specific therapeutic regimens. With current molecular testing applied in clinical practice, an increasing number of SBRCTs are found to lack the canonical EWSR1-FLI1 fusion typical of ES. This subset of EWSR1-fusion-negative undifferentiated SBRCTs has become the focus of significant investigation and debate recently, as on one hand they share significant overlap at the morphologic, immunophenotypic, and clinical levels with classic ES but on the other display different genetic signatures, complicating diagnosis and clinical management.
The present study further expands the genetic spectrum of SBRCTs, with 2 novel fusions, BCOR-MAML3 and ZC3H7B-BCOR, identified in cases that have remained unclassified after extensive immunohistochemical and molecular testing. The BCOR-MAML3 fusion was identified by RNA sequencing in an index case of a round cell sarcoma, negative for EWSR1, FUS, and CIC-related abnormalities. As seen with the BCOR-CCNB3, 9 the entire coding sequence of BCOR is also represented in the BCOR-MAML3 fusion transcript. The BCOR gene, located at Xp11.4, encodes a ubiquitously expressed transcriptional repressor that associates with the BCL6 oncoprotein and with a variety of histone-modifying enzymes, resulting in direct gene silencing by a unique combination of epigenetic modifications. 26, 27 BCOR has a key role in the regulation of early development, hematopoiesis, 28 and mesenchymal stem cell function. 29 In human diseases, BCOR is targeted by both mutations and translocations: somatic BCOR mutations are implicated in a subset of acute myeloid leukemia, 30 whereas germline BCOR mutations cause the oculo-facio-cardio-dental X-linked syndrome, 31 characterized by microphthalmia, congenital cataracts, dysmorphic appearance, radiculomegaly, and cardiac and digital defects. Gene fusions involving BCOR, with either CCNB3 or ZC3H7B partner genes, are involved in several translocation-associated mesenchymal lesions, such as BCOR-CCNB3 ES-like sarcomas 9 and ossifying fibromyxoid tumor (OFMT) and endometrial stromal sarcoma, respectively. 20, 25 The finding of identical chromosomal translocations in diverse pathologic and clinical entities such as SBRCT, endometrial stromal sarcoma, and OFMT adds to the growing list of otherwise unrelated entities that share genetic abnormalities. Moreover, a BCOR-RARA fusion has been described in acute promyelocytic leukemia. 32 The BCOR gene partner, MAML3, encodes for a member of the mastermind-like (MAML) family of transcriptional coactivators. They constitute a component of the Notch signaling pathway, an evolutionarily conserved pathway with roles in diverse biological processes such as cell proliferation, differentiation, and survival. 33 A recurrent PAX3-MAML3 fusion has been identified recently in a high percentage of biphenotypic sinonasal sarcoma cases (19/25 cases, 79%), 34 a low-grade sarcoma characterized by neural and myogenic differentiation, preferentially occurring in the sinonasal area of middleaged patients. 35 Similar to this fusion, the BCOR-MAML3 transcript in our SBRCT1 contains the exons 2 to 5 of MAML3, which retains the transactivation domain but loses the Notch-binding site of MAML3. Furthermore, the other BCOR gene partner, ZC3H7B, zinc finger CCCH domain-containing protein 7B, encodes for a nuclear protein that contains a tetratricopeptide repeat domain and interacts with the rotavirus nonstructural protein NSP3. 36 The ZC3H7B protein has several domains that are involved in protein-protein and proteinnucleic acid interactions and, particularly, in multiprotein complexes. Although neither of the 2 SBRCTs with ZC3H7B gene rearrangement identified by FISH had tissue available for RT-PCR and fusion transcript structure confirmation, one of the cases showed an unbalanced rearrangement, which was in keeping with ZC3H7B as 5' and BCOR as the 3' partner ( Supplementary Fig. 1 , Supplemental Digital Content 2, http://links.lww.com/ PAS/A330). The prior reported evidence of ZC3H7B-BCOR fusion in either endometrial stromal sarcoma or OFMT obtained from RNA sequencing 20, 25 points to the 3' position of BCOR, based on both unbalanced FISH pattern and predominance of the ZC3H7B-BCOR isoform detected by RT-PCR in a subset of these cases. The reported transcripts to date suggest the ZC3H7B exon 10 being fused to either exon 7 or 8 of BCOR.
Comparing the transcriptional profile of the BCOR-MAML3-positive index case with that of previously published gene signatures of ES and CIC-DUX4-positive sarcomas, 7 there was only limited transcriptional overlap Genes overlapping between BCOR-MAML3 and EWSR1-FLI1-positive tumors included NKX2-2, TYMS, TOP2A, EZH2, and ITGB3BP. Among the genes highly upregulated in the BCOR-MAML3-positive index case were transcription factors of the HOX/homeobox family ( Supplementary Fig. 2 , Supplemental Digital Content 3, http://links.lww.com/PAS/A331), important for development of the body plan for axis formation. 37 Intriguingly, BCOR was also shown to have a role in normal laterality determination, as patients with oculo-facio-cardio-dental syndrome triggered by BCOR germline mutations exhibit defective lateralization including dextrocardia, asplenia, and intestinal malrotation. 38 Altogether, 8/75 (11%) patients in our cohort of SBRCTs were positive for a BCOR rearrangement on using the BCOR break-apart FISH assay. In 2 cases each, BCOR was fused to either MAML3 or ZC3H7B genes. Although the number of cases is small, clinicopathologic data indicate a wide age range (5 to 70 y), almost exclusive occurrence in male patients, and distribution among bone and soft tissue sites. Tumor size tended to be large, and the clinical data available indicated an aggressive clinical course with multiple metastases or local recurrence despite intensive chemotherapy and radiotherapy ( Table 1 ). The morphology of the BCOR-rearranged SBRCTs consisted of primitive, undifferentiated cells with a round, oval to spindled cell appearance. The latter spindle cell component was present in variable degrees in most cases, either forming well-defined fascicles, reminiscent of the fibrosarcoma herring-bone growth, or more often as a vague streaming or patternless pattern. The nuclear features included fine, stippled chromatin and mild variability in size and shape. The stromal component was typically scant, but when discernible varied from delicate collagenous to fibromyxoid. Although CD99 staining was seen in most cases, it was typically weak and patchy.
Among the 85 SBRCTs of our cohort lacking EWSR1, FUS, SYT, and CIC gene rearrangements, 11 cases (13%) were positive for the BCOR-CCNB3 paracentric inversion, using a FISH assay specifically designed to detect the inversion. We reviewed the additional 42 cases of BCOR-CCNB3-positive SBRCTs from the literature (Table 3) , [9] [10] [11] [12] for a combined meta-analysis of 53 cases. The clinicopathologic data indicate predominant occurrence in the male population (M:F ratio, 4:1), a median age at diagnosis of 13 years (range, 2 to 44 y), and preferential localization within bone (38/53, 72%). RT-PCR techniques for detection of BCOR-CCNB3 fusions or CCNB3 immunohistochemistry are excellent and reproducible tools for diagnosis of these tumors. 9 Neither technique, however, is appropriate for detecting the alternative BCOR-MAML3 or ZC3H7B-BCOR fusions; these instead must be identified by FISH techniques using BCOR-specific break-apart BAC probes.
In summary, we identified recurrent BCOR gene rearrangements in 11% of SBRCTs lacking other genetic abnormalities. In this novel subset, BCOR-MAML3 and ZC3H7B-BCOR represent 2 novel alternative fusions, which have not been reported in SBRCTs previously. These fusions add to the growing list of fusion genes recurrently found in SBRCT with ES-like morphology, although they may have different pathogenetic mechanisms of tumorigenesis, as the BCOR gene participates either with its entire coding sequence (BCOR-MAML3, BCOR-CCNB3) or only with its 3' portion (ZC3H7B-BCOR) to the chimeric fusion. Additional functional studies are needed to further dissect the consequences of these different transcript structures. Tumors harboring BCOR gene rearrangement occur preferentially in young adults and have a wide anatomic distribution. Morphologically, these lesions show a monomorphic/primitive appearance, ranging from small blue cells to spindle cells arranged in intersecting fascicles or patternless growth. Immuno- histochemical workup is mostly noncontributory, with CD99 often being positive but with a weak and patchy distribution. The presence of alternating round and spindle cell components appears distinct from most other fusion-positive SBRCTs, thereby displaying morphologic overlap with a poorly differentiated synovial sarcoma. It remains to be seen whether the increasingly detailed pathologic subclassification of SBRCTs can be matched by the development of more effective histotype/genotypespecific therapies in these aggressive tumors.
